'Painful' regulations keeping Google on the periphery of life sciences; Catalent lines up for an IPO worth $100M--or much more;

Biotech IT News

> 'Painful' regulations keeping Google on the periphery of life sciences. Story

> Venter hires Google machine learning expert to build Translate for genomics. Article

> Buzz: Google Ventures leading $100M round in oncology Big Data platform. More

> Google joins genomics alliance as it prepares industry-focused cloud services. Report

> Medidata stung by $4.8M wire transfer fraud. Item

CRO News

> Catalent lines up for an IPO worth $100M--or much more. Article

> Big Pharma megadeals could spell trouble for CROs. Story

> Report: Indian clinical trials fell 93% last year. More

> Catalent shoots for $872M in a blockbuster IPO. Report

> InVentiv signs on to market 3-D printed drugs. Item

Animal Health News

> Will Zoetis stand alone when Big Pharma's music stops? More

> Lilly divests U.S. animal health assets to Virbac ahead of Novartis deal. Article

> FierceAnimalHealth: Bringing a unique approach to the animal health industry. Editor's Corner

> Five questions for Aratana CEO Steven St. Peter. Editor's Corner

> Merck releases tilapia vaccine. Story

Biotech Research News

> The top 10 biomedical research institutions. Special Report

> Top 15 NIH-funded disease areas. Special Report

> 10 drugs that could stop Ebola. Special Report

> Notable academic-pharma alliances of 2014. Special Report

> Diabetes culprit may be a single enzyme. Article

PharmaManufacturing News

> Teva recalling more than 1M bottles of generic Cymbalta. Article

> Saline shortage: FDA works with Baxter, Hospira and Braun. Report

> Sun Pharma plant joins the FDA list of banned Indian facilities. Story

> FDA says Apotex India plant has faked data for years. More

> Merck again shipping BCG cancer treatment but Sanofi still is not. Item

Drug Delivery News

> MIT, MicroCHIPS develop remote-controlled contraceptive with on-off delivery. Report

> Alnylam COO on Novartis RNAi pullout: Big Pharma has 'never been able to innovate.' Story

> AstraZeneca looks to pen injector approval to turn Bydureon diabetes sales around. Article

> Arrowhead doses first RNAi hepatitis B 'functional cure' PhIIa patient. More

> Roche's delivery method 'shuttles' Alzheimer's drugs past the blood-brain barrier. Item

Diagnostics News

> Illumina, AstraZeneca, Janssen and Sanofi to pursue universal companion Dx test. Article

> GE Healthcare's Dineen: A quest for new acquisitions will continue. Report

> J. Craig Venter raises $70M for a gene-sequencing and therapeutic startup. Story

> British startup finishes quick and easy Ebola test. Item

> GE Healthcare, FBI allege Chinese engineer stole MRI trade secrets. More

Pharma Marketing News

> The top 10 pharma companies in social media. Special Report

> 10 big brands keep pumping out big bucks, with a little help from price hikes. Article

> Why are Anoro and Breo slow starters? GSK's new quota-free model, critics say. Story

> Bristol-Myers gets the approval Gilead didn't want: Daklinza + Sovaldi for hep C. More

> BMS sues ex-account manager, claiming she took PD-1 marketing secrets to Merck agency. Item

Vaccines News

> CDC warns H1N1 virus is causing severe flu in young adults. Article

> Agenus' genital herpes vax cuts viral load 75% in PhII. Story

> Buzz: Merck and Novartis trying to iron out details of business unit swap. Report

> Top 10 best-selling vaccines of 2013. Special Report

> Sanofi dengue vaccine filings could come as soon as next year's Q1, CEO says. More

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.